I-Mab gets new CEO after long search. Sale of the company coming next?
The drug developer filled an 18-month-long vacuum in its top position by appointing an industry veteran with a history of deal-making as its new CEO Key Takeaways: I-Mab has appointed…
I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
I-Mab Founder Retakes Reins in Latest Shakeup Ahead of Commercialization Phase
Drug maker announces latest senior appointments as investors anticipate regulatory approval for some of its products as early as 2023 Key takeaways Four-year company veteran and CEO Joan Shen to…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Joyy stuck with unwanted China business after $3.6 billion Baidu sale collapses
YY.US
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Ascentage Pharma soars on deal with cancer drug competitor
6855.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
